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Colorectal cancer (CRC) is the third commonest cancer in the
world, accounting for about 9% of new cancer cases per year
(Schottenfeld and Winawer, 1996). The putative very long
duration of the adenoma to carcinoma sequence gives an ample
opportunity to detect and treat precursors of CRC, and to reduce
incidence and mortality from CRC (Gore, 1997). 
Several screening methods are currently available and recom-
mended to a varying degree in different countries (Anwar et al,
1998; Bond, 1999; Read and Kodner, 1999). They include faecal
occult blood testing (FOBT), digital rectal examination, double-
contrast barium enema, flexible or rigid sigmoidoscopy and
colonoscopy. So far, results from large-scale prospective random-
ized trials are available only for FOBT, with reduction of CRC
mortality by up to one third for annual FOBT screening (Towler
et al, 1998; Mandel et al, 1999). The potential for reduction of
CRC incidence and mortality is probably considerably higher for
the endoscopic examinations with removal of early cancers or
precancerous lesions as needed. Several epidemiologic studies
from the US (Gilbertsen and Nelms, 1978; Newcomb et al, 1992;
Selby et al, 1992; Winawer et al, 1993; Müller and Sonnenberg,
1995; Slattery et al, 2000) and one small randomized trial from
Norway (Thiis-Evensen et al, 1999) have shown substantial risk
reduction for up to 10 years following sigmoidoscopy or
colonoscopy, but so far there are no data on risk reduction beyond
10 years after endoscopy. Large-scale randomized trials have
recently been initiated to assess prevention of CRC morbidity and
mortality by screening endoscopy, but results on long-term effects
will not be available for another 10 or 20 years. 
The aim of this case–control study from Germany was to assess
reduction of CRC risk over a long-term period (up to and beyond
10 years) following a single screening endoscopy. 
MATERIALS AND METHODS 
Study design and study population 
A population-based, statewide study on the use of screening and
diagnostic procedures was conducted among patients with various
forms of cancer in Saarland, a state with about one million inhabi-
tants in Western Germany (Verlauf der diagnostischen Abklärung,
VERDI). Details of the study, which was primarily designed to
address factors determining diagnostic delay and late stage diag-
nosis, have been reported elsewhere (Arndt et al, 2001). Briefly,
residents of Saarland with a first diagnosis of colorectal cancer
(CRC), gastric cancer and breast cancer below age 80 between
November 1996 and February 1998 were recruited. 34 of 36 hospi-
tals in Saarland and the adjacent counties participated in recruit-
ment. Among 957 eligible patients recruited by these hospitals, 16
patients (1.7%) could not be enrolled because they died before an
interview could be scheduled, and another 33 patients (3.4%)
because they did not agree to participate. Overall, 908 patients
(439 patients with CRC, 82 patients with gastric cancer and 387
patients with breast cancer) living in Saarland were enrolled. The
study was approved by the Ethics Committees of the University of
Ulm and of the Physicians’ Boards of the state of Saarland and the
adjacent state of Rheinland Pfalz. 
In this case–control analysis previous history of screening
endoscopy was compared between patients with CRC and patients
with the other forms of cancer. Separate and joint analyses were
carried out for women and men. For both sexes, the case group
included patients aged 45–80 with a first diagnosis of colorectal
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cancer (ICD-9 153, 154). Patients below 45 years were excluded
because CRC is very rare and screening measures are typically
only considered among special risk groups in this age group. For
women, the control group consisted of those with breast cancer
(ICD-9 174) within the same age range. For men, the control
group consisted of 45–80-year-old men with gastric cancer (ICD-9
151). 
To avoid potential detection bias resulting from increased detec-
tion of tumours among subjects more ready to participate in
screening examinations and because the endpoint of interest was
reduction of clinically manifest CRC, we further excluded 175
patients (79 cases, 96 controls) whose cancer was detected by
screening measures or incidentally (e.g. in the context of another
health examination). We excluded 6 subjects with a history of
inflammatory bowel disease and another 11 patients with a history
of more than one screening endoscopy within the previous 5 years,
because these patients might have undergone repeat endoscopic
screening examinations due to increased risk of CRC. Screening
history was missing for 19 patients, leading to a final sample size
of 320 cases and 263 controls for this analysis. 
Data collection 
Patients were informed about the study by their physicians during
the first hospitalization with cancer, typically several days to
weeks after initial treatment. After informed consent was obtained,
patients were reported to the study center in Saarbrücken, the
capital of Saarland, and interviews were scheduled to be conducted
by one of three trained interviewers during hospitalization. 
Interviews were conducted following a standardized question-
naire. Questions included detailed information on medical
history, symptoms, diagnostic measures, previous screening
examinations, sociodemographic factors, and potential risk
factors of the cancer. Detailed information on the onset of the
first symptoms leading to the current cancer diagnosis was
obtained. Patients were asked if they had had a large bowel
endoscopy for screening purposes in the past, that is, before the
onset of the first symptoms leading to the current cancer diag-
nosis. No distinction was made between primary screening by
endoscopy, or endoscopic screening following another screening
examination, e.g. a positive FOBT. In case of a history of endo-
scopic screening, the time of the last screening endoscopy was
obtained, and the time between the last screening endoscopy and
the current cancer diagnosis was calculated. No distinction
between flexible or rigid sigmoidoscopy and colonoscopy was
made. 
Only examinations that were unrelated to the recent cancer
diagnosis, i.e. endoscopies that were done before the onset of the
first symptoms leading to the current cancer diagnosis and those
explicitly conducted for screening purposes were considered for
this analysis. Therefore, and because only cases with a first
diagnosis of CRC were included, our results show risk reduction
following a negative screening endoscopy (that is, endoscopy
without identification of CRC, but with potential identification
and removal of precancerous lesions). Information on cancer loca-
tion, spread and histology was extracted from the medical records. 
Statistical methods 
We first described cases and controls with respect to basic clinical
and sociodemographic characteristics and potential risk factors for
CRC. 
We then compared the history of screening endoscopy
between cases and controls. In all analyses, subjects without a
history of screening endoscopy formed the reference group. The
association between history of endoscopy and risk of CRC was
quantified by time since last screening endoscopy (≤ 5
years/5–10 years/≥ 10 years) using odds ratios and their 95%
confidence intervals (Weiss et al, 1992). Multiple logistic regres-
sion was employed to adjust associations for potential
confounding factors. The following covariates which were
known or suspected to be related to the risk of CRC and which
might also be related to history of screening endoscopy were
considered: age (in years), family history (history of CRC in a
first degree relative), school education (≤ 9 years/> 9 years),
marital status (married/other), smoking (current/former/never)
and alcohol consumption (no/yes). To take general health behav-
iour into account, we further controlled for history of a general
health examination, a screening examination focusing on cardio-
vascular disease, diabetes and nephropathy offered every two
years to adults above age 36 in Germany since 1989. 
In addition to the main analyses, separate analyses were carried
out for early (Dukes A or B) and advanced (Dukes C or D) CRC
and for rectosigmoidal and other CRC. 
Table 1 Characteristics of cases and controls 
Women Men Total 
Cases Controls Cases Controls Cases Controls 
Tumour site colon/rectum breast colon/rectum stomach colon/rectum breast/stomach 
Number of patients n = 132 n = 229 n = 188 n = 34 n = 320 n = 263 
Age (mean) 65.7 61.3 65.4 65.2 65.5 61.8 
Education > 9 years 11% 18% 24% 9% 19% 16% 
Married 51% 58% 87% 82% 72% 61% 
Family history of CRC 14% 5% 15% 6% 15% 5% 
Smoking former  23% 22% 62% 64% 46% 28% 
Current 11% 11% 14% 18% 13% 12% 
Alcohol consumption 85% 86% 94% 88% 90% 86% 
Participation in general health examination 62% 62% 68% 68% 65% 63% 
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RESULTS 
Overall, 320 patients with CRC aged 45–80 were included in this
analysis (132 women, 188 men, Table 1). The proportions of CRC
patients with localized cancer (Dukes A and B), regional (Dukes C)
and distant (Dukes D) tumour spread were 54%, 28% and 19%,
respectively. Controls were 229 women with breast cancer and 34
men with stomach cancer. The median time between onset of symp-
toms and definite diagnosis was 2 months for CRC cases, 1 month
for breast cancer controls and 3 months for gastric cancer controls.
Mean age of CRC cases was about 66 years (Table 1). Both female
and male controls were on average somewhat younger (61 and 65
years, respectively). The proportion of married subjects and of
former smokers were higher among men than among women, but
there were only minor differences between cases and controls within
both genders (the difference in the proportion of married women is
essentially due to the age difference between cases and controls).
Current smoking was rare, and alcohol consumption was common
among cases and controls in both women and men. About two third
of all participants reported at least one previous general health
examination, with very little differences between cases and controls.
By contrast, a major difference between cases and controls was
found for a family history of CRC (15% in cases, 5% in controls),
which reflects the well known familial aggregation of CRC. 
A previous history of screening endoscopy was more often
reported by controls (27%) than by cases (11%) (Table 2). This
pattern was observed in both genders, and further analyses were
combined for both genders. A pooled estimate of the odds ratio (OR)
of 0.30 (95% confidence interval, CI: 0.18–0.50) was obtained for
the association between history of a negative screening endoscopy
and risk of CRC after adjustment for gender. This estimate was
essentially unchanged by additional control for the other covariates
in multiple logistic regression (OR = 0.28, 95% CI: 0.16–0.48). 
In Table 3, analyses are further stratified by time since last
screening endoscopy. Although risk reduction was strongest
(about 80%) for subjects with a screening endoscopy within the
last 10 years (with little difference between time windows ≤ 5 and
5–10 years), a considerable risk reduction by about 60% was also
seen for subjects who had their last endoscopy more than 10 years
ago (median 18.9 years). 
Further analyses by tumour spread suggested long-term (> 10
years) risk reduction to be particularly strong for advanced tumour
stages Dukes C and D (OR = 0.19; 95% CI: 0.06–0.64), and both
short- (≤ 10 years) and long-term (> 10 years) risk reduction to be
stronger for rectosigmoid (OR = 0.21; 95% CI: 0.09–0.46 and OR
= 0.34; 95% CI: 0.14–0.87, respectively) than for other large
bowel cancers (OR = 0.29; 95% CI: 0.11–0.77 and OR = 0.70;
95% CI: 0.26–1.86). However, these results among subgroups of
cases need to be interpreted with caution given the width of the
confidence intervals. 
DISCUSSION 
Our results are consistent with and extend findings of several
epidemiologic studies from the United States which reported a
strong reduction of incidence and mortality of distal CRC within up
to 10 years following screening endoscopy (Gilbertsen and Nelms,
1978; Newcomb et al, 1992; Selby et al, 1992; Müller and
Sonnenberg, 1995; Slattery et al, 2000). To our knowledge, this is the
first study that addressed risk reduction beyond 10 years following
screening endoscopy, and it revealed that a strong reduction of CRC
risk by about 60% prevails well beyond 10 years indeed. 
Our study included virtually all hospitals and the majority of
patients within a defined geographic area. This approach implies
that the results probably more adequately reflect possible risk
reduction on the population level than the often somewhat more
Table 2 History of screening endoscopy among cases and controls 
Women Men Total 
Cases Controls Cases Controls Cases Controls 
n = 132 n = 229 n = 188 n = 34 n = 320 n = 263 
History of screening endoscopy 10 (8%) 62 (27%) 25 (13%) 8 (24%) 35 (11%) 70 (27%) 
OR (95% CI)a 0.22 (0.11–0.45) 0.50 (0.20–1.22) 0.30 (0.18–0.50)b
0.28 (0.16–0.48)c
aOdds ratio (95% confidence interval); bAdjusted for gender; cadditionally adjusted for age, family history of colorectal cancer, school education, marital status,
smoking, alcohol consumption, and participation in general health examination. 
Table 3 Time since last screening endoscopy among cases and controls 
Time since last screening
Odds ratio (95% confidence interval)  endoscopy
Interval Median
Cases Controls 
Adjusted for gender Adjusted for multiple covariatesa n = 320 n = 263
No endoscopy – 89.1% 73.4% 1.0reference 1.0reference
≤ 5 y 2.9 y 3.4% 10.3% 0.27 (0.12–0.62) 0.20 (0.08–0.49) 
5–10 y 7.0 y 2.5% 7.2% 0.23 (0.09–0.60) 0.23 (0.08–0.66) 
> 10 y 18.9 y 5.0% 9.1% 0.40 (0.19–0.85) 0.41 (0.19–0.89) 
aAdjusted for gender, age, family history of colorectal cancer, school education, marital status, smoking, alcohol consumption, and participation in general health
examination. 
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optimistic results obtained from highly specialized clinical
settings. Because subjects who were too sick to be interviewed
were not eligible for recruitment (and another – though very small
– proportion of patients died before interviews could be sched-
uled), subjects with advanced cancers are likely to be somewhat
under-represented in our sample. As long-term risk reduction
appears to be even stronger for advanced than for early cancers,
this may have led to some underestimation of long-term risk
reduction following a screening endoscopy. 
We used cancer rather than population controls. The validity of
the results therefore depends on the assumption that patients with
breast and stomach cancer do not differ from the general population
with respect to history of screening endoscopy (but not on the
assumption that these patients do not differ from the general popula-
tion with respect to CRC risk). There is no obvious reason, why a
history of previous large bowel screening endoscopy (performed
before onset of first symptoms) should be related to breast cancer or
stomach cancer. This point is supported by the consistency of our
findings with other, population-based studies that have assessed risk
reduction within 10 years following screening endoscopy. The fact
that participation in general health screening examinations was
virtually identical in cases and controls in our study suggests that
bias due to differential health consciousness is also unlikely. 
An advantage to the use of cancer rather than population
controls is that interviews could be realized in exactly the same
setting by the same trained interviewers following a standardized
questionnaire which should reduce bias due to differential recall, a
major problem in case–control studies relying on population
controls. 
History of screening endoscopy in this German population does
reflect individual patient management rather than screening within
the context of a primary endoscopic screening programme. A
nationwide screening programme for CRC offering annual FOBT
and digital rectal exam to women and men above 45 years was
introduced in Germany in 1977 (Wahrendorf et al, 1993). The
programme does not include endoscopy as primary screening tool,
but positive FOBT results are typically followed up by
colonoscopy. History of screening endoscopy reported in this
study includes, but is not restricted to evaluation of positive FOBT
screening results. Because patients with increased risk of CRC
may be more prone to undergo screening endoscopy, we excluded
patients with a history of inflammatory bowel disease, and care-
fully controlled for indicators of increased risk of CRC, such as a
positive family history. We cannot exclude, however, that the risk
reduction following screening endoscopy might have been under-
estimated to some extent due to residual confounding. 
Our results show risk reduction following a ‘negative’ screening
endoscopy, that is, endoscopy without identification of CRC, but
with potential identification and removal of precancerous lesions.
This has to be distinguished from the potential additional benefit
of ‘positive’ screening endoscopy, which would be mediated by
early treatment of screening detected invasive CRC (Weiss, 1999;
Imperiale et al, 2000; Lieberman et al, 2000). The definitive goal
of cancer screening is to reduce cancer mortality, and therefore
fatal cancer is the most important endpoint for evaluation of poten-
tial screening examinations. For CRC, mortality is strongly related
to stage at diagnosis, with 5-year relative survival rates ranging
from 80–90% for Dukes A and B tumours to about 5% for Dukes
D tumours (Wingo et al, 1998). In our analysis, overall risk reduc-
tion was almost identical for Dukes A and B and Dukes C and D
tumours, and long-term risk reduction appeared to be particularly
strong for the latter. This suggests that long-term reduction of fatal
CRC following negative screening endoscopy should be at least as
strong as reduction of incident CRC. 
A limitation of our study is that history of screening endoscopy
was based on self-reports and could not be validated by medical
records, a difficulty commonly encountered in epidemiologic
studies looking at lifetime history of medical procedures (a
substantial proportion of which dates back a very long time).
However, screening history was carefully ascertained by trained
medical staff in our study. Furthermore, large bowel endoscopy is
an invasive procedure that should be well remembered by most
patients, and high validity of self reported colorectal cancer
screening history has been demonstrated empirically (Gordon
et al, 1993; Baier et al, 2000). However, no reliable information
about findings at screening examinations could be obtained, and no
definite distinction could be made between sigmoidoscopy and
colonoscopy. The pattern of a less strong risk reduction for prox-
imal colon cancer than for rectosigmoid cancer appears plausible
given that no risk reduction for proximal colon cancer would be
expected among those study participants who underwent sigmoi-
doscopy only. This implies, on the other hand, that reduction of
proximal colon cancer might be much stronger in the subgroup of
patients who underwent colonoscopy. 
This is the first study on long-term effects of screening
endoscopy, and its results have to be replicated in other popula-
tions. If confirmed in other studies, our results may have important
public health implications: firstly, our results support the case for
implementation and evaluation of endoscopy as primary
screening tools in CRC screening programmes (Atkin, 1998;
Lieberman, 1998). Unlike the FOBT, which often fails to identify
patients with precancerous lesions, large bowel endoscopy has
the potential of substantial CRC prevention through identifica-
tion and removal of adenomatous polyps. Secondly, our analysis
supports the suggestion, that the strong protective effect of endo-
scopic screening with removal of precancerous lesions is long-
lasting, and that this effect may be achieved with long-term
screening intervals. In particular, our results confirm and extend
the notion that a follow-up endoscopy would usually not be
necessary for at least another 10 years unless there are specific
indications for it (Atkin et al, 1992; Hoff et al, 1996). Very effec-
tive prevention of advanced CRC manifestations which account
for the vast majority of CRC deaths may even be achieved with
longer screening intervals. The possibility to extend screening
intervals to 10 years or even longer suggested by our results
might strongly enhance the feasibility, acceptance, reduction of
side effects and cost effectiveness of population-wide endo-
scopic screening (Sonnenberg et al, 2000). This particularly
applies to colonoscopy which is more invasive than other
screening procedures, but which provides the possibility to
detect and remove precancerous lesions in the entire large bowel. 
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